On Dec. 30, 1993, the Genentech drug Pulmozyme (dornase alfa) was approved by the U.S. Food and Drug Administration (FDA) with an an Orphan Drug Designation. Pulmozyme is a nebulized cystic fibrosis (CF) treatment option to help manage CF symptoms.